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Seven transmembrane receptors (7TMRs) are nature’s prototype allosteric proteins made to bind molecules at one location to
subsequently change their shape to affect the binding of another molecule at another location. This paper attempts to
describe the divergent 7TMR behaviours (i.e. third party allostery, receptor oligomerization, biased agonism) observed in
pharmacology in terms of a homogeneous group of allosteric behaviours. By considering the bodies involved as a vector
defined by a modulator, conduit and guest, these activities can all be described by a simple model of functional allostery
made up of the Ehlert allosteric model and the Black/Leff operational model. It will be shown how this model yields
parameters that can be used to characterize the activity of any ligand or protein producing effect through allosteric
interaction with a 7TMR.
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Seven transmembrane receptors (7TMRs) are proteins resid-
ing on the cell surface to transmit chemically coded informa-
tion to the cell. They do so through ligand-induced changes
in conformation that are read by other proteins in the
cytosol. This is a general mechanism of protein function
referred to as allosterism. By definition, allosteric interactions
on proteins occur through the binding of a molecule to affect
the free energy of conformation of the protein where this
subsequently affects its behaviour towards the cell or other
molecules. When a molecule binds to a receptor protein, the
energy of the protein changes irrespective of how relatively
small the molecule is in relation to the protein. This change
in energy can lead to a change in the behaviour of the
receptor. This paper will discuss 7TMRs in terms of allosteric
protein function in an attempt to unify their complex behav-
iour through general concepts.
Receptor states and models
Early models of 7TMR function denoted the mechanics
of receptor function through the formation of an ‘active’
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receptor state. These approaches to describe agonist effect
utilized linkage models so called because they identify the
protein species present and link them with isoenergetic
pathways. The resulting models parsimoniously defined a
minimum number of receptor states for lack of data to indi-
cate otherwise; that is, there usually was only a single cellular
readout (e.g. tissue response) for the presence of receptor
active states. These models were referred to by the number of
defined spontaneously formed states (e.g. R and R*) and given
identities such as ‘two-state’ models.
As technology progressed to yield assays that measure
multiple 7TMR-mediated drug responses, it has become
evident that different ligands can ‘traffic’ stimulus to different
cellular pathways with varying emphasis. This phenomenon,
commonly referred to as functional selectivity or biased
agonism (vide infra), has been proposed on theoretical
grounds to be due to the agonist-selective formation of dif-
ferent receptor conformations (Kenakin, 1995); at present,
the effect has been observed for many receptor types (for
reviews, see Gurwitz and Haring, 2003; Hermans, 2003;
Kenakin and Miller, 2010). These effects will be discussed
later in this paper, but for the present discussion, it is relevant
to note that such trafficking phenomena are incompatible
with the mediation of 7TMR response through a single recep-
tor active state. This appears to be in conflict with the parsi-
moniously named ‘two-state’ models used to describe
receptor action, but this conflict is only apparent. It should be
noted that the two states described in the two-state model
refer to spontaneously formed receptors (inactive and active);
once a ligand binds to the receptor, a thermodynamically
distinct new state of the receptor is formed. Under these
circumstances, a condition of multiple receptor active states
is actually not incompatible with the existing linkage models
of receptor function notwithstanding their limited nomen-
clature. This is because the thermodynamic parameters defin-
ing the changes in receptor reactivity (see Figure 1) actually
can define a very large number of receptor states through the
modification of receptor affinity for coupling protein such as
G-proteins with parameters such as a (for the extended
ternary complex model – Samama et al., 1993) and g and d
(cubic ternary complex model – Weiss et al., 1996a,b,c).
Therefore, far from being ‘two-state’ models, these are multi-
state models that are capable of describing complex 7TMR
behaviours towards ligands and cells. In spite of this fact, it
should still be recognized that linkage models are limited in
their description of receptor systems due to the requirement
that they pre-define the receptor species present in the
system. It will be seen that this requirement is inconsistent
with protein behaviour as given by molecular dynamics that
describe proteins as spontaneously sampling numerous con-
formations in response to the energy of the system. Thus,
proteins can be thought of as existing in systems of multiple
conformations such that at any instant, a snapshot of the
system would yield a collection of conformations referred to
as an ensemble. While linkage models can accommodate
multiple ligand states of the receptor, they require pre-
identification of multiple spontaneously formed receptor
conformations, and this leads to complex models containing
many unverifiable parameters; multiple protein conforma-
tional ensembles are better seen through probabilities of state
formation (Onaran and Costa, 1997; Onaran et al., 2002).
However, for the purposes of characterizing allosteric drug
parameters, it will be seen that linkage models furnish the
tools to ascribe numbers to modulators to guide medicinal
chemistry.
7TMRs as allosteric machines
The full spectrum of 7TMR behaviour towards ligands and
cells includes complex probe-dependent cooperative interac-
tion between co-binding ligands, oligomerization on the cell
surface and biased cell signalling. All of these effects can be
described economically in terms of considering 7TMRs as
allosteric machines, and it is worth defining the elements of
7TMR signalling systems in this light. A basic tenet of this
approach is to view allostery as a transfer of energy, through
the protein, between two sites of interaction with external
bodies. A useful terminology for this type of system is to view
one of the bodies as a ‘modulator’ transmitting energy
through a ‘conduit’ (the receptor protein) to a ‘guest’ (the
other external body binding to the protein). This transfer of
energy is vectorial (i.e. a modulator producing a change in
the behaviour of a guest) but must be considered bidirec-
tional; that is, modulators and guests are interchangeable
with the nomenclature existing only to define a given 7TM
function. Thus, a modulator agonist could increase the affin-
ity of a receptor for a G-protein guest (a vector directed
towards the cytosol) or, equally a G-protein modulator could
increase the affinity of the receptor for an agonist guest
(vector aimed to the extracellular space). The energy flow is of
equal magnitude. A representation of such a modulator/
conduit/guest system is shown in Figure 2 where a modulator
binds to its own site on the receptor (conduit) to alter the
effect of a guest, in this case an agonist. It should be noted
that all 7TMR agonism is allosteric with all agonists being
Figure 1
Linkage models for receptor function. Receptors are assumed to exist
in two states: active (with respect to coupling to G-proteins to induce
response denoted [Ra]) and inactive ([Ri]). The ligand A binds to the
receptor thereby co-binding with G-proteins. It can be seen that the
presence of ligand A on the receptor changes the interaction con-
stants of the receptor by a factor a for the extended ternary complex
model and dg for the cubic ternary complex model. Since a and dg
values can be unique to the ligand A, this allows each ligand to
stabilize a unique conformation. The term ‘two state’ thus refers only
to the species Ra and Ri and not to the response capability of the
system in the presence of agonists.
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modulators affecting the response of the protein to cytosolic
signalling proteins as guests (vide infra).
It is also useful to consider the vectorial nature of allos-
teric effect to classify 7TMR behaviours. Figure 2 shows guest
allostery whereby the reactivity of a protein towards two
molecules is affected by the binding of those same molecules;
the binding of one of the molecules affects the binding of the
other. This is the earliest form of allosterism described as in,
for example, the inhibition of metabolic enzymes by struc-
turally diverse products of subsequent enzymes in a meta-
bolic pathway. These effects led to the postulate that proteins
can be modulated through binding of molecules at more than
one location (Umbarger, 1956). There also are allosteric
vectors directed along the plane of the cell membrane, which
mediate interactions between two or more receptors to
produce receptor oligomers (Bouvier, 2001; Angers et al.,
2002; James et al., 2006; Milligan et al., 2006). These effects
also can involve a receptor and other membrane bound
protein such as a RAMP (receptor activity modifying protein
– Hay et al., 2006). There are different kinds of allosteric
systems that can result from cell surface receptor oligomer-
ization. For instance, a receptor could itself function as a
modulator to modify an existing agonist/receptor/G-protein
system (Figure 3A). Alternatively a receptor may dimerize to
form a new conduit and thereby construct a system whereby
a ligand binding to one protomer affects signalling mediated
by the other protomer (Figure 3B). There is a great deal of
literature describing the function of 7TMR homodimers and
heterodimers, which are beyond the scope of this present
paper (for reviews, see Breitwieser 2004; Franco et al. 2008;
Giraldo 2008; Gurevich and Gurevich 2008; Milligan 2008).
Finally, the allosteric vector may be directed into the cytosol;
as discussed previously, every 7TMR agonist is an allosteric
modulator. As seen in Figure 4, cytosolic signalling proteins
such as G-proteins, GRKs, b-arrestin and other coupling pro-
teins form the array of guests for the modulator/conduit pairs
on the cell surface.
The binding of molecules to separate sites leads to a per-
missive system with unique properties that emanate from
the allosterically modulated receptor (with both ligands
co-bound). Specifically, the behaviour of the modulator-
bound protein can differ for various co-binding ligands,
leading to one of the most important features of allostery,
namely that of probe dependence. For example, considering the
endogenous ligand as a probe of receptor function, a given
allosteric modulator can have variable effects on different
probes. A second important feature of allostery is saturation of
effect. Unlike competitive mechanisms where effects can con-
tinue as long as different quantities of the interactants are
added to the system, allosteric effects cease when the allos-
teric site on the protein is saturated. The properties of probe
dependence and saturation of effect form the basis of 7TMR
complex behaviours discussed in this paper.
There are no pre-set rules for how a given allosteric modu-
lator should affect receptor probes. For example, receptor
responsiveness can be reduced to yield allosteric antagonism.
Figure 2
An allosteric system consisting of a modulator binding to the recep-
tor (conduit) to affect the interaction of a guest with the same
receptor. The modulator and guest nomenclature is interchangeable
since the energy of interaction through the conduit is equal magni-
tude and bidirectional. The modulator/guest nomenclature identifies
a vector for purposes of identifying specific receptor effects.
Figure 3
Complexation of receptors along the plane of the cell membrane. (A)
Receptor functioning as a modulator to affect the interaction of an
agonist with another receptor and signalling guest molecules in the
cell. (B) Receptor hetero- or homodimer functioning as a new
conduit to allow a modulator (agonist) for one receptor to affect a
signalling interaction with the other protomer in the dimer.
Figure 4
Allosteric system with the allosteric vector directed towards the
cytosol. Modulators (agonists) bind to the conduit to transmit energy
to cytosolic signalling proteins as guests. The conformation of the
conduit dictates differential interaction with each guest to produce
possible bias in activation.
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An important feature of allosteric antagonists is that they
come to a maximal asymptotic effect (when the allosteric site
is fully occupied). Under these circumstances, the maximal
effect they have on a receptor system is determined by
co-operativity factors (vide infra). For example, a surmount-
able allosteric antagonist produces dextral displacement of
agonist dose–response curves that come to a maximal value,
causing distinct curvature of the derivative Schild regression
(Christopoulos and Kenakin, 2002). Similarly, the principle of
probe dependence dictates that different probes may be
affected in different ways; that is, an allosteric antagonist may
block some agonists but not others. Allosteric modulators
also can increase the responsiveness of protein targets; these
molecules are referred to as positive allosteric modulators
(PAMs). Such potentiation is also subject to probe depen-
dence as seen in the agonist dependent and pathway
dependent effects of the PAM NOVO2 (6,7-dichloro2-
methylsulfonyhl-3-tert-butylaminoquinoxaline). This modu-
lator produces differential potentiation of the natural
agonists GLP-1(7-36)NH2 and oxyntomodulin (vide infra) and
can even change the quality of agonist signal produced by the
activated receptor. Specifically, while both of these agonists
produce signalling through cAMP and calcium, NOVO2
potentiates cAMP but not calcium (Koole et al., 2010). In
general, the unique allosteric properties of saturation of effect
and probe dependence lead to a highly flexible array of
7TMR-ligand behaviours that allow 7TMRs to be efficient
signal transmitters both for natural ligands and also for
synthetic molecules aimed at therapeutic effect. It is worth
considering how these properties can be exploited in drug
discovery.
Unique effects of allosteric modulators
Orthosteric molecules (i.e. antagonists, inverse agonists) pre-
clude access of other molecules such as agonists to the recep-
tor resulting in a pre-emptive system. This leads to a common
maximal result for all such antagonists, namely an inacti-
vated (or in the case of partial agonists, a partially activated)
receptor to all agonists. In contrast, allosteric molecules are
permissive in that they potentially allow interaction of the
protein with other molecules. This effect and the property of
saturation of effect cause allosteric modulators to have a
unique range of activities. These are:
a. Allosteric modulators have the potential to
alter the interaction of very large proteins
When two large proteins interact, there often are multiple
areas of contact. It would be expected that it would be diffi-
cult for an orthosteric ligand, binding to a single location on
the protein to disrupt such an interaction through steric
hindrance. In this sense, an orthosteric molecule is defined as
one binding to the natural binding site for the endogenous
ligand. An allosteric ligand binding to a separate site on the
protein by definition produces an effect on the orthosteric
binding site through a change in protein conformation.
There are data to show that allosteric ligands can stabilize
new global conformations of the receptor, and this has the
potential to alter the position of numerous areas of the
protein. Under these circumstances, it would be predicted
that multiple binding loci would be affected. An example of
this type of effect is the blockade of the interaction of the
chemokine CCR5 receptor and the HIV-1 virus coat protein
gp120 by the allosteric ligand aplaviroc (a molecule 1/200 the
size of the proteins that binds to a site different from those
binding chemokines and HIV-1) to prevent HIV-1 infection
(Watson et al., 2005).
b. Allosteric modulators have the potential to
modulate but not completely activate and/or
inhibit receptor function
Allosteric modulators can produce limited effects on target
proteins because complete occupancy of the allosteric site
produces saturation of effect. Unlike an orthosteric antago-
nist, an allosteric antagonist modulator can reduce the
responsiveness of a target without completely blocking its
function. Saturability of effect can lead to another property of
modulators, namely the possibility of dissociating the length
of time the effect is operative (i.e. target coverage) and the
intensity of effect. Under these circumstances, high doses of a
limited allosteric antagonist can yield a pool of drug to give
long-lasting response without overdose.
c. Allosteric modulators have the potential to
preserve physiological patterns
While direct agonism produces blanket activation of systems,
PAMs potentiate the existing responses in proportion to the
natural physiological tone. This may have relevance to
organs such as the brain where failing complex patterns of
neurological signalling may need to be augmented (as in
diseases such as Alzeimer’s).
d. Allosteric modulators may yield therapies
with reduced side effects
In therapies where augmentation of physiological effect is
required, PAMs would be expected to have a lower side-effect
profile. This is because they produce no direct effect but
rather have actions only when the system is active through
natural presence of the endogenous agonist.
e. Allosteric antagonists can produce texture
in antagonism
While orthosteric antagonists all produce a common end
product upon saturation of binding (namely an inoperative
biological target), allosteric antagonists produce antagonism
through alteration of protein target conformation. Since
these alterations in conformation need not be identical, dif-
ferent allosteric modulators could produce pharmacological
blockade through production of different receptor species.
For example, it has been shown that for the CCR5 receptor,
the antibody binding profiles of Ab45531 and Ab45523 differ
in the presence of the allosteric HIV-1 entry inhibitors
TAK779, SCH-C and aplaviroc, suggesting that these modu-
lators produce different tertiary conformations of the CCR5
receptor (Kenakin, 2007).This may be of importance in dis-
eases such as AIDs where it is expected that HIV-1 viral muta-
tion eventually will lead to tolerance to an HIV-1 entry
inhibitor as the virus mutates to a form that can utilize the
BJP TP Kenakin
1662 British Journal of Pharmacology (2012) 165 1659–1669
allosterically modified receptor (Trkola et al., 2002; Kuhmann
et al., 2004). Therefore, once resistance to one type of modu-
lator is observed, therapy with another modulator that pro-
duces a different conformation might be beneficial.
f. Allosteric modulators can have separate
effects on agonist affinity and efficacy
Allosteric changes need not be in the same direction (antago-
nism or potentiation), leading to the possibility that an allos-
teric modulator could change agonist affinity in one direction
and efficacy in another. For example, the CCR5 allosteric
modulator aplaviroc minimally affects the binding of the
chemokine CCL5 to the receptor but completely blocks
CCL5-mediated agonism (Maeda et al., 2004; Watson et al.,
2005). Thus, while the high affinity binding of CCL5 is not
greatly affected by aplaviroc (suggesting that G-protein
binding is not altered by the allosteric effect), the steps
leading to G-protein activation and subsequent cellular
response are completely blocked. This is consistent with
aplaviroc having little effect on CCL5 affinity but a strong
negative effect on CCL5 efficacy. This is similar to the
effect of the ester CPCCOEt (7-hydroxyiminocyclopropan[b]
chromen-1a-carboxylic acid ethyl ester), which completely
blocks the responses to glutamate in CHO cells naturally
expressing human GluR1b receptors while not affecting
glutamate binding (Litschig et al., 1999). One particular com-
bination of these activities can be useful, namely an allosteric
antagonist modulator that increases agonist affinity but
decreases agonist efficacy; this combination could lead to a
molecule that becomes more potent with higher agonist con-
centrations. This is because allosteric energy flow is reciprocal
in nature; that is, if the modulator increases the affinity of the
agonist, then the agonist will also increase the affinity of the
modulator in a like manner; this has been shown experimen-
tally (Trankle et al., 1999). Therefore, the presence of higher
agonist concentrations will promote allosteric antagonist
binding and lead to greater antagonism. This profile can be
seen with antagonists such as ifenprodil (for NMDA recep-
tors; Kew et al., 1996) and Org27569 (for cannabinoid recep-
tors – see Price et al., 2005).
g. Allosteric modulators may have an
extraordinary selectivity for receptor types
Physiological orthosteric binding sites for endogenous
ligands (neurotransmitters, hormones) may be highly con-
served between receptor subtypes, making it difficult to attain
selectivity through interaction at this site. This conservation
is not necessary for allosteric binding sites, and these may be
more diverse between subtypes of receptor (Melchiorre et al.,
1989; Ellis et al., 1991; Liang et al., 1996; Gnagey et al., 1999;
Johnson et al., 2004).
h. Allosteric modulators exercise
‘probe dependence’
Since allosterism involves a change in the shape of the
protein, it is possible that a change in shape that is cata-
strophic to the activity of one probe (i.e. agonist) may have
no effect at all on another, especially if those probes bind to
different regions of the protein. For instance, the CCR5 allos-
teric modulator aplaviroc produces very little effect on the
binding of the chemokine CCL5 to the receptor but com-
pletely blocks the binding of the chemokine CCL3 (Watson
et al., 2005). This effect has implications both for the thera-
peutic application and mode of discovery of allosteric modu-
lators. Regarding how allosteric modulators are discovered
and developed, probe dependence dictates that the endog-
enous ligand targeted therapeutically should be used in the
screening and discovery process. For example, a PAM may be
of use in augmenting a failing cholinergic neuronal transmis-
sion in Alzheimer’s disease (Maelicke and Albuquerque, 1996;
Krause et al., 1998). However, the natural agonist (acetylcho-
line) is chemically unsuitable for use in many drug discovery
screens and subsequent experiments thus stable analogues,
namely carbachol and/or pilocarpine are often used in
the screening process. However, PAMs such as LY2033298
have been shown to cause agonist-dependent differential
potentiation of different agonists such as acetylcholine and
oxotremorine (Suratman et al., 2011). In general, the existing
data suggest that if the natural agonist (such as acetylcholine)
cannot be used in the screening process, then the modulator
should be tested with it as early on in the discovery and
development process as possible. This also is relevant to PAMs
for targets with multiple natural agonists. For example, while
the anti-diabetic PAM NOVO2 produces a fivefold potentia-
tion of one of the natural agonists for the GLP-1 receptor
GLP-1(7-36)NH2, it produces a 25-fold potentiation of oxyn-
tomodulin, another natural agonist for this receptor (Koole
et al., 2010). These data suggest that all agonists for a given
receptor need be tested when studying the effects of allosteric
modulators. With regard to the impact of probe dependence
on therapeutic application of allosteric modulators, the pos-
sibility exists that a given modulator will block or potentiate
the endogenous agonist and have no effect on other agonists.
For example, HIV-1 utilizes the CCR5 chemokine receptor to
cause infection and CCR5 allosteric antagonists block this
effect. Interestingly, however, it has been shown that allos-
teric modulators have varying relative activities of for HIV-1
blockade versus chemokine-induced blockade of CCR5 inter-
nalization (Muniz-Medina et al. 2009). Specifically, CCR5
allosteric modulators have differing relative potency as block-
ers of HIV entry and CCL5-induced CCR5 internalization.
This texture of antagonism could be useful in AIDs therapy as
it has been shown that the CCR5 chemokine receptor medi-
ates favourable protection in progression to AIDs after HIV-1
infection (Gonzalez et al., 2005). This suggests that a superior
allosteric modulator would block the utilization of CCR5 by
HIV-1 but otherwise allow normal chemokine function for
this receptor; this is possible with allosteric modulators
(Muniz-Medina et al. 2009).
Quantifying allosteric effect
Allosteric effects can be quantified by comparing dose-
response curves, obtained in the presence of different con-
centrations of allosteric modulator, to a model. The most
simple model for doing this is an amalgam of the Ehlert
model of allosteric receptor effect (Ehlert, 1988) and the
Black/Leff operational model of receptor function (Black and
Leff, 1983). These have been combined to yield a model that
can describe the functional effects of allosteric modulators
BJP7TMRs as allosteric proteins
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(see Ehlert, 2005; Kenakin, 2005; Price et al., 2005). A sche-
matic diagram relating the relevant elements is given below,
showing receptors (R) bind to a receptor probe (agonist, A)
and an allosteric modulator (B):
(1)
Allosteric modification of effect is quantified by two
co-operativity factors, namely a and b. The term a quantifies
the effect of the modulator B on the affinity of the receptor to
A (and similarly the reciprocal effect on affinity that A has on
the affinity of B). The term b quantifies the effect the modu-
lator has on the efficacy of A. It can be seen from this model
that an allosteric modulator cannot be characterized by only
affinity (KB-1) but rather will also have a type of ‘efficacy’ for
the receptor and its interaction with A in the form of a and b.
A concise and flexible form of this model has been for-
mulated by Leach et al. (2007) to furnish the equation that
incorporates salient aspects of direct effects (allosteric
agonism) and modification of co-binding agonist effects of
allosteric modulators:
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where Em is the maximal response capability of the system, tA
is the efficacy of the co-binding probe agonist, KA and KB the
equilibrium dissociation constants of the agonist and
antagonist–receptor complexes respectively and n a fitting
factor for the curves. This model also has the capability of
describing direct agonism for the modulator; tB refers to the
efficacy for direct agonism of the allosteric modulator.
It is worth exploring the capability of this model in terms
of the characterization of allosteric modulators. Considering
modulators that have no direct agonist effect, there are three
possible effects (increase, no effect and decrease) on affinity
(a) and efficacy (b) of the agonist. This leads to (3 ¥ 3) - 1
possible combinations of effect; these are shown in Figure 5.
It can be seen that every possible effect on dose–response
curve location parameter (EC50) and/or maxima can be
described by equation 2. It also shows that a full description
of the allosteric effects of a modulator requires three esti-
mates: KB (the concentration of modulator that binds to the
receptor protein), a (effect on affinity of the co-binding
ligand) and b (effect on efficacy of the co-binding ligand).
Obviously, some of these will be unique to the particular
co-binding ligand.
With regard to modulator binding, the potency of an
allosteric modulator activity is described by an affinity con-
stant (pKB) much like other antagonists. However, since allos-
teric systems describe the energy of interaction between two
molecules acting on the protein, the effective affinity of the
modulator is modified by the a factor provided by the
co-binding ligand. Under these circumstances, it can be seen
that different a factors for different ligands can lead to
varying affinity; that is, the affinity of the modulator is con-
tingent upon the nature of the co-binding ligand. Similarly,
the functional effect of an allosteric modulator also depends
upon the value of b since this defines the effect of the modu-
lator on the efficacy of the co-binding agonist. In practice,
therapeutically targeted allosteric modulators deal with
endogenous agonists; therefore, a single set of pKB, a and b
values for the endogenous ligand may be sufficient for char-
acterization. However, in the case of multiple endogenous
ligands (such as the situation for some peptide receptors),
complications may arise as the activity of the allosteric modu-
lator may vary for different endogenous ligands. These ideas
also suggest that it may be difficult to relate binding data to
function unless it is assured that the nature of the guests and
the relative stoichiometry of the conduit to guest in the
experimental system will be identical to the physiological
system.
Allosteric modulators stabilize conformational states of
proteins, and these may also have direct effects in their own
right. Therefore, allosteric modulation also can be associated
with direct agonism. A pure allosteric agonist binds to its own
site on the protein and stabilizes an active state; this process
can be independent of the process of natural agonism pro-
duced by the endogenous agonist. Since the allosteric agonist
does not interfere with the binding of the endogenous
agonist, the resulting allosteric agonism will be additive
to endogenous agonism. However, since allosterism may
produce a global change in the protein conformation, there is
no a priori reason why an allosteric agonist could not also
produce a modified endogenous agonist response. If the allos-
teric modulator has direct agonist effect, then 3 ¥ 3 possibili-
ties exist for unique combinations, the added one being
where the modulator has no effect on the co-binding agonist
(a = b = 1) but where the allosteric agonism is additive to the
system. These various effects are shown in Figure 6.
Detecting allosteric effect
Allosterism can produce surmountable or insurmountable
antagonism that can closely resemble that seen with conven-
tional orthosteric ligands under certain circumstances. It is
useful to consider techniques that can differentiate allosteric
from orthosteric effects since the identification of ligand
mode of action is valuable in predicting therapeutic value.
Utilizing quantitative models of antagonism there are three
general concepts that are useful in identifying allosteric
modes of action:
1 Prediction of acute effect
2 Adherence to predicted pattern(s)
3 Probe/concentration exploration
Clearly, the first prerequisite is to identify a quantitative
model that describes the effect of the ligand on the observed
agonist dose–response curve (point 1, prediction of effect).
However, this is a loose criterion as many allosteric antago-
nists produce surmountable and/or insurmountable effects
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identical to those seen with conventional orthosteric block-
ers. However, fitting data for a range of antagonist concen-
trations (point 2, adherence to predicted pattern) is a more
stringent criterion since the pattern of antagonism produced
by allosteric antagonists often differs from that seen with
orthosteric antagonists. For instance, a surmountable allos-
teric antagonist of a = 0.1 produces a maximal 10-fold shift to
the right of agonist dose–response curves, while a simple
competitive antagonist produces a much larger maximal
dextral displacement. This illustrates the basic allosteric prop-
erty of saturation of effect; that is, the effect ceases when the
allosteric site is maximally bound. The third idea is an exten-
sion of this one, namely the use of as large a range of con-
centrations as possible to detect possible saturation of effect.
In addition, as many receptor probes as possible (i.e. agonists
or radioligands) should be utilized to detect possible probe
dependence. Thus, if antagonism is limited or varies with
different agonists (or radioligands), then allosterism is indi-
cated. Finally, it should be noted that all of these are ‘one-
way’ experiments in that the converse is not necessarily true.
If no saturation and/or probe dependence is detected, it still
may be that low values of a or b are operative (so that
saturation occurs at only very, very high concentrations) or
the wrong probes were used in attempts to detect probe
dependence. It should be pointed out that definitive evidence
of allosteric effect is to show differences in the kinetics of
interaction of receptor probes in the presence of the sus-
pected allosteric modulator (i.e. Leach et al. 2011).
Figure 5
Possible outcomes of effect for allosteric modulators with no direct agonist activity; curves calculated with equation 2 (Em = 100; t = 3; n = 1.6;
KA = 10 mM; KB = 10 nM). Panels from top row–left: (a = 30/b = 5) (a = 1/b = 5) (a = 0.01/b = 5), middle row–left (a = 30/b = 1) (a = 30/b = 1)
(middle panel, no curves: (a = 1/b = 1) (a = 0.01/b = 1), bottom row–left (a = 30/b = 0.3) (a = 1/b = 0.3) (a = 0.01/b = 0.3).
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Biased signalling in allosteric terms
There are data to show that agonists can vary in their capa-
bility to activate different signalling pathways in cells; this
has been generally referred to as ‘functional selectivity’ or
‘biased agonism’. These effects can be applied to antagonists
as well. Discussion of the applicability of these effects to new
drug discovery is beyond the scope of this paper but has been
reviewed in numerous papers (Hermans, 2003; Kenakin,
2003, 2011; Perez and Karnick, 2005; Leach et al., 2007;
Mailman, 2007; Kenakin and Miller, 2010). It will be assumed
that these effects are directed from the receptor and thus will
transfer to all tissues possessing that receptor. Under these
circumstances, biased signalling, if controlled through
medicinal chemistry, has the potential of being a relevant
approach to selective pharmacologic therapies. Currently,
due to the fact that there are relatively few biased ligands in
clinical studies, it is premature to judge the importance of
this approach. For the purposes of this discussion, the mecha-
nism of action of biased signalling will be considered.
The first theoretical mechanism proposed for biased sig-
nalling suggested that different agonists stabilize different
receptor conformations, and that these interact differentially
with coupling proteins to induce signalling emphasis in cells
(Kenakin, 1995). There are data utilizing a number of experi-
mental approaches to support the existence of numerous
ligand-specific receptor conformations (see Kenakin and
Miller, 2010 for further discussion) consistent with the con-
formational hypothesis for biased signalling. Such a mecha-
nism also is consistent with the allosteric nature of 7TMR
function. As pointed out previously, the ability of a modula-
tor to affect guests differentially is a known feature of allos-
Figure 6
Possible outcomes of effect for allosteric modulators with direct agonist activity; curves calculated with equation 2 (Em = 100; t = 3; n = 1.6;
KA = 10 mM; KB = 10 nM; tB = 0.25). Panels from top row–left: (a = 30/b = 5) (a = 1/b = 5) (a = 0.01/b = 5), middle row–left: (a = 30/b = 1) (middle
panel; a = 1/b = 1) (a = 0.01/b = 1), bottom row–left (a = 30/b = 0.3) (a = 1/b = 0.3) (a = 0.01/b = 0.3).
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tery (probe dependence). Therefore, while classical guest
allosterism and biased agonism have been described in the
literature as an apparently separate phenomenon, it should
be noted that functional selectivity is nothing more than a
cytosolically directed allosterism.
It is interesting to note how the model describing func-
tional allosterism (equation 2; no direct modulator agonism
present, tB = 0) also describes biased agonism. This can be
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where [j] is the amount of signalling protein and takes the
place of agonist [A] in equation 2, response is considered to
the amount of receptor-coupling protein complex [jR], n is a
curve fitting factor and Em the maximal response capability of
the system. It is assumed that there is a finite capability of the
unliganded receptor to interact with the signalling protein in
the form a t value ([Rt]/KE where [Rt] is the total density of
receptors and KE is the Black/Leff equilibrium dissociation
constant of the unligand receptor-coupling protein complex).
This then allows the ‘agonist’ to be a modulator [M] with an
equilibrium dissociation constant for the receptor of KM. The
agonist affects the interaction between receptor and signal-
ling protein through the parameters a and b just as any
modulator would in a conventional guest allosteric system.
Thus, a controls the change in affinity of the receptor and
signalling protein produced by the modulator and b the
change in signalling quality (efficacy) of the complex in pro-
ducing response. Simply by redefining the species, it can be
seen that signalling bias can be described by the allosteric
model as delineated by equation 2.
Figure 7 shows two hypothetical responses (one labelled
cAMP and the other b-arrestin complexation) and the
responses to two agonists (modulators 1 and 2). For a con-
stant set of system parameters (Em, t, n), each agonist has a
Figure 7
Biased agonism in terms of the functional allosteric model. (A) The agonist is a modulator labelled M interacting with a receptor conduit, which
also interacts with two guests labelled Ga (for a cAMP response) and b-arrestin for an association with b-arrestin. (B) Upon binding of agonist M,
the affinity of the conduit changes in accordance with aG and aB for the particular agonist. The quality of action of the couplers also changes in
accordance with bG and bB. (C and D) System parameters: Em = 1; [j] = 0.001 for G-protein/0.002 for b-arrestin; n = 1.6; t = 1 for G-protein / 0.3
for b-arrestin. Kj = 0.03 for both G-protein and b-arrestin. For agonist 1 (modulator M1: KM = 10-6 for unliganded receptor, a = 2000; b = 0.3).
For agonist 2 (modulator M2: KM = 10–6 for unliganded receptor, a = 1000; b = 0.6). (E) Bias plot of b-arrestin response (ordinates) as a function
of cAMP response (abscissa) for agonists 1 and 2 from panels C and D.
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distinct set of KM, a and b values (in accordance with probe
dependence). It can be seen that these agonists do not have
the same capability to activate each pathway; that is, they are
biased towards the pathways with respect to each other. At
this point, it is useful to define and differentiate system bias
from ligand bias. System bias relates to how well coupled any
two signalling pathways are in a cell. All systems will be seen
to be biased since the relative activity of ligands for two
pathways will depend upon the nature of the cell, the relative
stoichiometry of signalling proteins and receptors and how
the experiment is conducted. However, what is meant by
functional selectivity is that, within a given experimental
system bias, some ligands demonstrate a selective ability to
activate one of the pathways when compared with another
ligand. This can be shown with a bias plot as shown in
Figure 7E, which shows the response to one pathway as a
function of an observed response to the other pathway. It can
be seen that modulator 2 yields a straight line (in this par-
ticular case there is little system bias), whereas modulator 1
produces much more b-arrestin response per unit response of
cAMP. That is, it is a b-arrestin-biased agonist.
Conclusions
This discussion illustrates how the allosteric nature of recep-
tors accounts for all their known behaviours. It also suggests
that the characterization of ligand activity on 7TMRs and the
nomenclature of 7TMR ligands are complex processes. As
distinctive 7TMR ligand profiles are identified, it will be
extremely interesting to see how (or even if) they compare
with clinical therapeutic phenotypes.
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